Tommaso Schirinzi, Alberto Romano, Martina Favetta, Andrea Sancesario, Riccardo Burattini, Susanna Summa, Gessica Della Bella, Enrico Castelli, Enrico Bertini, Maurizio Petrarca, Gessica Vasco.
1. The aim of this open label pilot study was to evaluate the feasibility, safety and effectiveness of NIFMV by WS in a cohort of 10 patients with childhood ataxia, a phenomenological category including different conditions still lacking of effective symptomatic therapies.
2. Through the assessment of both clinical rating scales and spatio-temporal gait parameters via standardized gait analysis, we observed that a 4 weeks long treatment with WS Equistasi® was safe and provided significantly different effects in stride features of patients with slow/non-progressive cerebellar ataxia and Friedreich’s Ataxia.